echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Antibody drug conjugate DS-1062 study expanded to treat triple-negative breast cancer patients

    Antibody drug conjugate DS-1062 study expanded to treat triple-negative breast cancer patients

    • Last Update: 2020-07-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The First Three announced that its antibody drug Couple (ADC), which targets TROP2, is being evaluated for safety, tolerance and initial efficacy in patients with advanced non-removable or metastatic three-negativebreast cancer(TNBC)Photo Source:TROP2 (Feeding Layer Cell Surface Antigen 2) is a transmembrane glycoprotein that has been expressed in many cancers and has been expressed in 80% of triple-negative breast cancer patientsStudies have shown that high EXPRESSION OF TROP2 is associated with the growth and proliferation of cancer cells and the low survival rate of patientsTROP2 is considered to be a potential molecular target for a wide range of cancers"DS-1062 has achieved encouraging initial results in non-small cell lung cancer patients, and we are now expanding our research to study three-negative breast cancer patients to determine whether DS-1062, designed with our proprietary DXd ADC technology, has the potential to target new options for TNBC and other cancer targeted treatments," said Gilles Gallant, Global Head of Oncology research and development at theof theThe safety and tolerance of the increasing dose of DS-1062 was evaluated in the first part of thestudy to determine the maximum tolerable dose (MTD) and the recommended expanded dose (RDE) for the lateNSCLCpatientsThe second part of the study is further assessing the safety and tolerance of DS-1062 at the selected dosethe study is currently recruiting approximately 180 patients with advanced unremovable NSCLC in the United States and Japan who received doses of DS-1062 at doses of 4, 6 and 8 mg/kg, and about 40 patients with advanced non-removable or metastatic TNBC receiving 8 mg/kg doses of DS-1062safe endpoints include dose-limiting toxicity and severe adverse events Efficacy endpoints include objective remission rate, mitigation duration, disease control rate, mitigation time, no progression survival and overall survival Pharmacokinetics, biomarkers and immunity primary endpoints will also be assessed
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.